Dan Mangan is a reporter covering health care and other issues for CNBC.com.
Mangan has been a journalist for more than 20 years, most recently as a general assignment/rewrite reporter at the New York Post. In his more than dozen years at The Post, Mangan routinely covered major stories, including the 9/11 terror attacks, the Bernard Madoff Ponzi scheme, the 2008 financial meltdown and a slew of juicy Gotham scandals du jour, among them the personal tribulations of Yankee slugger Alex Rodriguez.
Prior to that, Mangan began his career in his native Connecticut, writing obituaries for The Hour of Norwalk, before moving on to cover business, government and the court systems at The Hour, the Fairfield County Business Journal and The Advocate of Stamford.
It's not clear when EpiPen owner Mylan was told by health officials it was misclassifying the anti-allergy device for rebate purposes.
Mylan's share of revenue from EpiPen due to Medicare and Medicaid more than doubled from 2011-2015.
Many hospitals in the path of the hurricane altered their operations.
People who sign up in Obamacare coverage outside open enrollment tend to spend less time enrolled in plans.
The federal government said Medicaid has spent nearly $800 million on EpiPens since 2011.
Mylan should be paying higher Medicaid rebates for its EpiPen devices, health officials say.
More than 2 million people would get subsidies to reduce their premiums, but aren't because they buy outside of Obamacare exchanges.
Congress demanded more documents about how much Mylan actually makes on EpiPen anti-allergy devices, which have skyrocketed in price.
Harken Health charges customers nothing out of pocket for primary care visits to the insurer's clinics, but it bled cash.
Older people are more at risk for the flu, but officials say everyone older than 6 months should get vaccinated.